PKCε Antagonists Modulate Insulin Clearance and Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for insulin resistance and glucose intolerance in Type II diabetes are inadequate, as the specific mechanisms involving protein kinase C (PKC) isoenzymes, particularly PKCε, in causing these conditions remain unclear, and existing treatments do not effectively address lipid-induced insulin resistance and β-islet cell dysfunction.
Innovation Solution
Reducing the activity or level of protein kinase C epsilon (PKCε) in the liver to decrease insulin clearance and enhance insulin secretion by pancreatic β-islet cells, using antagonist compounds identified through cell-based and animal-based drug screens, which protect β-islet cells from lipid-induced defects and improve glucose tolerance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for insulin resistance are used, then glucose intolerance is managed, but the specific mechanisms involving PKC isoenzymes remain unclear and treatment effectiveness is inadequate
Solution Approach 1:
The patent identifies PKCε as a key intermediary enzyme in the pathway between lipid accumulation and insulin resistance. By targeting this specific intermediary rather than treating symptoms, the invention achieves more reliable treatment outcomes while the mechanistic role of PKCε provides clear biological insight into the disease process
Solution Approach 2:
The invention changes the therapeutic parameter from general insulin resistance management to specific PKCε activity modulation. This parameter shift enables both improved treatment reliability through targeted therapy and enhanced mechanistic understanding through direct intervention at the molecular level
2Reliability
If lipid-induced insulin resistance is addressed, then glucose metabolism improves, but β-islet cell dysfunction persists
Solution Approach 1:
The patent converts the harmful effect of lipid accumulation on β-islet cells into a beneficial outcome by identifying PKCε as the mediator. Inhibiting PKCε not only addresses the lipid-induced damage but also protects against further β-islet cell dysfunction, turning a harmful pathway into a protective therapeutic target
Solution Approach 2:
The invention implements preliminary protection of β-islet cells from lipid-induced damage by targeting PKCε activity before complete cell dysfunction occurs. This preliminary intervention preserves cell function and prevents the progression to severe β-islet failure
3Productivity
If insulin clearance by the liver is reduced, then insulin secretion is enhanced, but the mechanism remains unclear
Solution Approach 1:
The patent identifies PKCε as the intermediary enzyme that mediates hepatic insulin clearance. By targeting this specific mediator, the invention simultaneously achieves enhanced insulin secretion through reduced clearance while providing clear mechanistic insight into the previously unclear hepatic insulin metabolism pathway
Data Source
AI summary
The present invention provides novel cell-based and animal-based assays for determining antagonists of PKCε and uses of the isolated antagonist compounds for modulating insulin clearance and secretion. The invention also provides novel animals and cells such as animals and cells suitable for use in the assays.